Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02986815 · ClinicalTrials.gov registry record · NA
[11C]Acetate PET in Patients With Glioma
A NA study, sponsored by University of Texas Southwestern Medical Center.
- Terminated
- Registry status
- NA
- Development phase
- 5
- Enrollment target
NCT02986815 is a NA study that was terminated before completion, run by University of Texas Southwestern Medical Center. The registered enrollment target is 5 participants.
The verdict
NCT02986815, a NA study, was terminated before completion, sponsored by University of Texas Southwestern Medical Center.
- TERMINATED
- Registry status
- NA
- Development phase
- 5 participants
- Enrollment target
Study Summary
At each point that the patient will have \[11C\]-Acetate PET study, this will be compared with standard clinical MR imaging. Abbreviations: XRT - radiation therapy; TMZ - temozolomide (chemotherapy) Quantitative Image Data Analysis: The \[11C\]-Acetate uptake in tumor sites from images will be analyzed qualitatively by visual assessment, quantitatively using a standard uptake value (SUV) in the tumor relative to the contralateral normal brain, and the parameters obtained by compartmental modeling of dynamic data.
Interventions
- OTHER [11C]Acetate Brain Imaging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2017-01-24 |
| Est. Completion | 2020-05-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02986815
The ClinicalTrials.gov registry entry for NCT02986815 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which [11C]Acetate Brain Imaging is the first listed.
NCT02986815 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02986815 about?
NCT02986815 is a clinical study titled "[11C]Acetate PET in Patients With Glioma". At each point that the patient will have \[11C\]-Acetate PET study, this will be compared with standard clinical MR imaging. Abbreviations: XRT - radiation therapy; TMZ - temozolomide (chemotherapy) Quantitative Image Data Analysis: The \[11C\]-Acetate uptake in tumor sites from images will be anal...
What is the current status of trial NCT02986815?
This trial is currently terminated. It is a NA study. The enrollment target is 5 participants. The study started on 2017-01-24. Estimated completion is 2020-05-05.
What interventions are being tested in trial NCT02986815?
The interventions under investigation include: [11C]Acetate Brain Imaging (OTHER).
Who is sponsoring clinical trial NCT02986815?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.